Recipharm locks in new development contracts leveraging its blow-fill-seal capabilities
Global contract development and manufacturing organization Recipharm announced that it has secured product development contracts that strengthen its position in blow-fill-seal (BFS) technology, a single continuous process within a sterile closed system in which containers are formed, filled, and sealed minimizing the risk of contamination.
The company said it has a new contract with a “top five” global ophthalmic organization that involves the rapid production of clinical trial material for a Phase 1 study, while it has also signed an agreement with a global ophthalmic biotech to support a Phase 2/3 ophthalmic suspension program.
Recipharm said the recent customer contracts will leverage four ophthalmic areas of expertise: BFS, pre-filled syringes, oral solid technologies, as well as product development services including analytical and stability support.
The company claims it is the only CDMO with BFS capabilities for both biologics and small molecules from early phase development through to commercialization, and that its clinical capabilities deliver over 90% active pharmaceuticals ingredient (API) savings compared to commercial manufacturing approaches.
“Recipharm’s BFS clinical platform is designed for speed, adaptability and efficient API use, enabling the delivery of high quality clinical trial material across Phases 1, 2 and 3,” Vincenza Pironti, head of business development, said in a statement. “Combined with our specialist expertise, we are empowering clients to bring innovative products to market faster and with greater confidence.”
Headquartered in Stockholm, Sweden, Recipharm operates 17 facilities in 10 countries around the world, giving it a global presence with local expertise that rivals some of the largest CDMOs, according to CEO Greg Behar, who took the company’s reins in January 2024.
Recipharm, which became private in 2021 and has more than 5,000 employees worldwide, is “one of the oldest CDMOs out there” and is the fifth largest CDMO globally serving the biopharma industry, Behar told Pharma Manufacturing in a profile of the company earlier this year. In 2024, it secured record-breaking revenue of €827 million, a 7% year-over-year increase driven by growth in its biologics business.
“We are partnering with eight out of the top 10 pharma,” Behar said, adding that in 2025 he projects that Recipharm will exceed last year’s results by achieving double-digit growth.